Skip to content
‹ Back to IndustriesSciences

How Does the COVID-19 Antiviral Medications Workflow Compare to the Traditional Antiviral Production Pipeline

The discussion focuses on comparing the traditional antiviral production pipeline to the workflow used for producing COVID-19 antiviral medications. Dr. Kishor Wasan shares insights into how COVID-19 vaccine research differs from past practices in antiviral and antibiotic production. The conversation aims to highlight the differences and similarities in treatment development for COVID-19 versus other viruses.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · AntibioticsAntiviralUniversity of British Columbia
Share
How Does the COVID-19 Antiviral Medications Workflow Compare to the Traditional Antiviral Production Pipeline

Key takeaways

01

Researchers are learning more about COVID-19 to effectively combat it.

02

Differences are noted in the COVID-19 vaccine production versus traditional antiviral pipelines.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

As the COVID-19 pandemic continues to progress researchers and scientists are starting to learn more about the virus in order to effectively combat it. One of those lessons is how the COVID-19 virus compares to other viruses when it comes to developing treatments. Justin Honore talked to Dr. Kishor Wasan, PH.D.,FAAPS, FCAHS, FCSPS, Chief Medical & Scientific Officer at Skymount Medical and a Distinguished University Scholar Adjunct Professor at the University of British Columbia about how COVID-19 vaccine research and production compare to the traditional antiviral and antibiotic production pipeline.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Agilent's new 5987A GC/MS takes aim at costly sample reruns

Agilent's new 5987A GC/MS takes aim at costly sample reruns

Agilent’s 5987A GC/MSD adds vendor-claimed up to 25% faster scanning and a wider detector range alongside GC Assist diagnostics tracking 60-plus parameters. Its design focuses on taking injections out of workflows to limit reruns. With helium spot prices reportedly doubling after the March 2026 disruption, avoided reruns can save gas, but EPA criteria checks and ISO/IEC 17025 verification still come first.

  • 01Injection-cutting features can matter most: MassHunter’s simultaneous dSIM/Scan to combine SIM quantitation and library-searchable full scan in one run, and Agilent’s claim of an order-of-magnitude wider dynamic range that could reduce dilution reinjections if it holds up in routine use.
  • 02Onboard diagnostics pay back unevenly. Labs that find faults by failing QC batches stand to gain the most, while labs on comprehensive service contracts may mainly change which contract tier they buy.
  • 03The up-to-40% energy cut applies with the IDP-4 pump, so bid scoring should confirm the quoted configuration before crediting the savings.

Nov 10, 2026

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Genmab's petosemtamab, added to Merck's Keytruda, cut the risk of death by 50% in 699 first-line head and neck cancer patients. The trial held regardless of HPV status. Full data will be presented at an upcoming medical meeting.

  • 01In a cancer where median survival runs about 10 to 12 months, adding petosemtamab to Keytruda halved the risk of death at the first interim look.
  • 02The benefit held regardless of HPV status, supporting use in PD-L1-positive patients without separating by HPV status.
  • 03The figure to watch at the full-data presentation is median overall survival in each arm, because the topline release reports only the hazard ratio.

Nov 9, 2026

UCB commits to Veeva Vault CRM platform

UCB commits to Veeva Vault CRM platform

UCB has committed to Veeva Vault CRM, which Veeva’s release presents as an agentic CRM platform to drive unified engagement worldwide. UCB and Veeva executives describe it as a stable foundation for UCB’s commercial strategy, while the AI claims, including the Agentic Call Report, come from Veeva’s product description. No go-live date or financial terms were given.

  • 01The executive statements focus on Vault CRM as a foundation. The AI pitch, including the Agentic Call Report, comes from Veeva’s product description.
  • 02Veeva says the Agentic Call Report turns field call records into "Commercial Evidence" about treatment barriers that went unseen before. If it works as described, call reports gain value when analyzed at scale.
  • 03No go-live date or financial terms were disclosed. A go-live date or first-market rollout from UCB would show whether a worldwide migration is moving.

Nov 7, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

S
Sciences
DK
Dr. Kishor Wasan

Chief Medical & Scientific Officer

Skymount Medical

Dr. Kishor Wasan is a Chief Medical & Scientific Officer at Skymount Medical. He is also a Distinguished University Scholar Adjunct Professor at the University of British Columbia.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512